MedTrace Logo

Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

NCT04400799 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 475

Last updated 2022-05-25

No results posted yet for this study

Summary

The OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces unplanned hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.

Conditions

  • COVID-19
  • Pulmonary Embolism, Deep Vein Thrombosis

Interventions

DRUG

Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml

daily incetion s.c. for 14 days

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER

  • University Hospital, Geneva

    collaborator OTHER

  • Centre Hospitalier Universitaire Vaudois

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • Oncology Institute of Southern Switzerland

    collaborator OTHER

  • Clinica Luganese Moncucco

    collaborator OTHER

  • University Hospital Freiburg

    collaborator OTHER

  • Mainz University

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Nils Kucher, Prof. · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-15
Primary Completion
2022-02-07
Completion
2022-04-12

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04400799 on ClinicalTrials.gov